Phase I/II Trial of Multiple Dose ¹³¹Iodine-MAb LL2 (CD22) in Patients with Recurrent Non-Hodgkin's Lymphoma

Abstract

The purpose of this to evaluate in a phase IAI study the efficacy and toxicity of a multi-dose administration of ¹³¹I labeled CD22 monoclonal antibody (¹³¹I-MAb-LL2) in escalating dose cohorts administered to relapsed non-Hodgkin's lymphoma (NHL) patients. Twenty-one patients with relapsed NHL received one of four dose levels of ¹³¹I-MAb-LL2 administered in a twice weekly pattern. Starting with dose level 2, the patients also received 20 mg of unla-beled LL2 prior to each radiolabeled dose administered. Previously stored autologous peripheral blood progenitors were reinfused in case of prolonged cytopenias. Patients could repeat the same treatment if they had stable disease or a response to the first therapy at 8 weeks, and had not received their peripheral blood progenitors with the first cycle. Combining all of the dose cohorts, there were 5 complete responses or complete responses (undetermined) and 2 partial responses for a total response rate of 7/21 (33%). There was no dose response effect with responses documented at all dose levels. Expected toxicities were hematopoietic, requiring stem cell re-infusion in 5 patients. Other toxicities included hypothyroidism in 3 patients, and human anti-mouse antibody formation (HAMA) in 4 patients. In conclusion, ¹³¹I-MAb-LL2, when administered in a multi-dose fashion with 20 mg unlabeled antibody pre-dosing, resulted in a response rate of 33% in heavily pre-treated NHL patients. Non-hematologic toxicities were mild and few in number. Further evaluation of this treatment is warranted and further dose escalation will be possible.

Key Words:

• ¹³¹Iodine labeled
• monoclonal antibody
• anti-CD22
• recurrent non-Hodgkin's lymphoma